Pharmaceutical company AmyriAD steps into the light with Phase III drug for relief of Alzheimer’s symptoms
BOSTON, November 10, 2021 / PRNewswire / – CTAD Conference – AmyriAD – a biopharmaceutical company led by the development strategist who introduced the cognition enhancing drug Aricept® – announced today that its lead candidate in the fight against Alzheimer’s disease (AD), AD101, will enter phase 3 trials in the second quarter of 2022. The new drug’s approach aims to complement the already existing treatment of AD by focusing on improving cognition and function through a single pathway, neuroselective T-type calcium channels.
AD is the most common cause of dementia and fifth leading cause of death in adults over 65, affecting 6 million people in United States alone. In 2020, the cost of AD care was more than US $ 500 million, the majority of which was unpaid care. By 2050, the economic cost of providing unpaid care is expected to skyrocket to US $ 1 trillion.
For 20 years, Aricept® has been the standard of care for AD. It dramatically improves cognition and overall function at all stages of the disease. Although these effects are long-lasting compared to placebo, neither Aricept® nor any other treatment has been shown to reduce the progression of AD.
“Research over the past 15+ years has focused on disease modification strategies relying on biomarkers as a proxy, as well as measures of patient function,” explained the CEO of ‘AmyriAD, Dr. Sharon roger. “These efforts have greatly improved our collective understanding of AD, and recent results from studies in enriched patient populations provide hope. Despite this, it is difficult to predict who will or will not succumb to AD. a large patient population continues to be a critical and under-satisfied medical need. “
By focusing on cognition and overall function, AmyriAD advances a drug which, when given in combination with Aricept®, demonstrated statistically significant additive relief in a randomized, double-blind, placebo-controlled phase 2 proof of concept. These beneficial effects were produced with an adverse event profile indistinguishable from placebo.
AD101 was initially discovered in the phenotypic tests of animal models of learning and memory. Mechanism of action studies subsequently demonstrated an increased release of acetylcholine through selective Ca antagonism.V3.1 and thatV3.3 voltage-dependent channels. This action also improved learning and memory in Aβ and tau dependent models while reducing the accumulation of both biomarkers in these animals.
AmyriAD develops drug therapies in conjunction with advanced diagnostics, digital staging assessments, and disease mitigation strategies. Our team brings together decades of experience with Alzheimer’s disease with the sole aim of mitigating the devastation it causes.
Learn more about https://amyriadtherapeutics.com/